Purines: from premise to promise.
Geoff Burnstock's remarkable insight and tenacity has established the area of purinergic research as a bona fide target for drug discovery. While efforts in P1 receptor-based medicinal chemistry and biology efforts over the past 25 years have not reached the level of success that the pharmaceutical industry investment may have anticipated, the P2 area, with knowledge of the selective localization of members of the P2X and P2Y family members and data from transgenic knockouts, has identified several potential therapeutic areas of major promise including cystic fibrosis, chronic bronchitis, male contraception and neurodegeneration. In addition, interest in the potential of purinergic therapeutics has extended outside the major pharmaceutical companies to the 'biotech industry' resulting in an environment where the inherent risks of 'first in field' in a therapeutic area may be more appropriately nurtured.
Williams
M
M
Neurological and Urological Diseases Research D 464, Pharmaceutical Products Division, AP9A/317 Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6125, USA. mike.williams@abbott.com
D000818:Animals; D004345:Drug Industry; D006801:Humans; D011687:Purines / Q000378:metabolism*; D011983:Receptors, Purinergic / Q000187:drug effects / Q000502:physiology*
D011687:Purines; D011983:Receptors, Purinergic